NYSEAM:LCTXBiotechs
Lineage Cell Therapeutics Q4 Profit Challenges Longstanding Loss Narrative
Lineage Cell Therapeutics (LCTX) has wrapped up FY 2025 with fourth quarter revenue of US$6.6 million and basic EPS of US$0.00, alongside net income of US$0.9 million. Its trailing twelve month figures show revenue of US$14.6 million and a net loss of US$63.5 million, equal to basic EPS of US$0.28. Over the past few quarters, the company has reported revenue of US$1.5 million in Q1 2025, US$3.7 million in Q3, and US$6.6 million in Q4. Basic EPS ranged from a loss of US$0.13 in Q2 and Q3 2025...